Under construction – not a live service
Sign in
Taking people in TürkiyeNo phase

Identifies adults with type 2 diabetes for possible future studies

Identifies adults with type 2 diabetes and reviews their medicine use.

Key facts

Who runs it
AstraZeneca
Where
Adana, Ankara, Gaziantep, Istanbul, and Kayseri, TürkiyeSee the 5 sitesAlso in 6 other countries, 61 sites
Trial code
Registry title
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
Status
Recruiting
People taking part
2,150 people, planned
Started
6 May 2026
Expected to end
31 Mar 2027
Type of study
Observational
Treatments tested
  • Procedure: assessment
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled, to find people for current or future type 2 diabetes studies.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Type 2 diabetes confirmed by a test or by documents, not well managed with lifestyle changes alone and/or with a stable dose of background glucose-lowering medicine.
Earlier treatment
If taking glucose-lowering medicine, the dose must have been stable for at least 45 days before signing the consent form.

Main reasons for not taking part

  • Current or planned use of GLP-1 RAs that are not allowed in the studies
  • Type 1 diabetes
  • Known pregnancy or plan to become pregnant

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants must be ≥ 18 years of age at the time of signing the ICF
  • Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World; Health Organization or local diagnostic standards, inadequately managed with:
  • Lifestyle management alone, AND/OR
  • A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF; Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required; Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis

Who cannot take part

  • Diagnosed with Type 1 diabetes mellitus
  • Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol)
  • Known pregnancy at the time of visit or having the intention to become pregnant

Where in Türkiye

Also in 6 other countries, 61 sites

  • AdanaHospital not named in the registryNot yet recruiting
  • AnkaraHospital not named in the registryTaking people
  • GaziantepHospital not named in the registryNot yet recruiting
  • IstanbulHospital not named in the registryNot yet recruiting
  • KayseriHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

The group in the trial

  • Participants with Type 2 Diabetes

    Treatment: Procedure: assessment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
Plain-language title
Identifies adults with type 2 diabetes for possible future studiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
25 August 2026